Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans

Journal of Clinical Pharmacology

Volumn 55, Issue 7, 2015, Pages 815-824

  Becker, Andreas ^a   Von Richter, Oliver ^a   Kovar, Andreas ^b   Scheible, Holger ^c   Van Lier, Jan J ^d   Johne, Andreas ^a  

^a Merck Serono GmbH   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c MERCK KGAA   (Germany)

^d Pharmaceutical Research Associates Group   (Netherlands)

Author keywords

cilengitide; disposition; human; mass balance

Indexed keywords

CARBON 14; CILENGITIDE; DRUG METABOLITE; ALPHAVBETA5 INTEGRIN; SNAKE VENOM; VITRONECTIN RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FECES LEVEL; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSGEUSIA; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RADIOACTIVITY; SINGLE DRUG DOSE; URINARY EXCRETION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; YOUNG ADULT;

ADULT; HUMANS; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; MALE; RECEPTORS, VITRONECTIN; SNAKE VENOMS; YOUNG ADULT;

EID: 84930628894     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.482     Document Type: Article

References (29)

1. Mas-Moruno C, Rechenmacher F, Kessler H,. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010; 10: 753-768.
2. Humphries JD, Byron A, Humphries MJ., Integrin ligands at a glance. J Cell Sci. 2006: 119: 3901-3903.
3. Desgrosellier JS, Cheresh DA., Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010; 10: 9-22.
4. Goodman SL, Picard M., Integrins as therapeutic targets. Trends Pharmacol Sci. 2012; 33: 405-412.
5. Taga T, Suzuki A, Gonzalez-Gomez I, et al., alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int J Cancer. 2002; 98: 690-697.
6. Paolillo M, Russo MA, Serra M, Colombo L, Schinelli S,. Small molecule integrin antagonists in cancer therapy. Mini Rev Med Chem. 2009; 9: 1439-1446.
7. Alghisi GC, Ponsonnet L, Rüegg C., The integrin antagonist cilengitide activates alphaVbeta3,disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells. PLoS One. 2009; 4: e4449.
8. MacDonald TJ, Taga T, Shimada H, et al., Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001; 48: 151-157.
9. Buerkle MA, Pahernik SA, Sutter A, Jonczyk A, Messmer K, Dellian M., Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo. Br J Cancer. 2002; 86: 788-795.
10. Smith JW., Cilengitide Merck. Curr Opin Invest Drugs. 2003 4: 741-745.
11. Nabors LB, Mikkelsen T, Rosenfeld SS, et al., Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007; 25: 1651-1657.
12. Eskens FA, Dumez H, Hoekstra R, et al., Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer. 2003; 39: 917-926.
13. Stupp R, Hegi M, Gorlia T, et al., Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15 (10): 1100-1108.
14. Rosano TG, Freed BM, Pell MA, Lempert N., Cyclosporine metabolites in human blood and renal tissue. Transplant Proc. 1986; 18 (6 Suppl 5): 35-40.
15. Keverling Buisman AS,. Handboek Radionucliden. 2nd ed. Bergen, Noord-Holland: BetaText; 2007: 25.
16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, bioanalytical method validation, May 2001. http://www.fda.gov/downloads/Drugs/./Guidances/ucm070107.pdf. Accessed February 3, 2015.
17. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on bioanalytical method validation, July 2011. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf. Accessed February 3, 2015.
18. Biron E, Chatterjee J, Ovadia O, et al., Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl. 2008; 47: 2595-2599.
19. Ovadia O, Greenberg S, Laufer B, Gilon C, Hoffman A, Kessler H., Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin Drug Discov. 2010; 5: 655-671.
20. Fahr A., Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet. 1993; 24: 472-495.
21. Kolars JC, Awni WM, Merion RM, Watkins PB., First-pass metabolism of cyclosporin by the gut. Lancet. 1991; 338: 1488-1490.
22. von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT., Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther. 2004; 75: 172-183.
23. Wacher VJ, Silverman JA, Zhang Y, Benet LZ., Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998; 87: 1322-1330.
24. Burckart GJ, Starzl TE, Venkataramanan R, et al., Excretion of cyclosporine and its metabolites in human bile. Transplant Proc. 1986 18;(6 Suppl 5): 46-49.
25. Maurer G., Metabolism of cyclosporine. Transplant Proc. 1985; 17 (4 Suppl 1): 19-26.
26. Maurer G, Lemaire M., Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc. 1986; 18 (6 Suppl 5): 25-34.
27. Christians U, Strohmeyer S, Kownatzki R, et al., Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile-isolation of 12 new cyclosporine metabolites. Xenobiotica. 1991; 21: 1185-1198.
28. Christians U, Strohmeyer S, Kownatzki R, et al., Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica. 1991; 21: 1199-1210.
29. van de Waterbeemd H, Smith DA, Jones BC,. Lipophilicity in PK design: methyl, ethyl, futile. J Comput Aided Mol Des. 2001; 15: 273-286.